Novo Nordisk A/S
Novo Nordisk A/S (NVO) Stock Competitors & Peer Comparison
See (NVO) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NVO | $45.38 | -3.90% | 207.5B | 12.43 | $3.65 | +3.50% |
| LLY | $746.37 | -2.56% | 707.6B | 60.90 | $12.26 | +0.74% |
| JNJ | $170.59 | -0.09% | 410.7B | 18.26 | $9.34 | +2.94% |
| ABBV | $196.30 | -1.13% | 346.7B | 93.47 | $2.10 | +3.32% |
| AZN | $73.60 | -1.18% | 228.2B | 27.67 | $2.66 | +2.07% |
| NVS | $113.50 | -3.59% | 220.8B | 16.55 | $6.86 | +3.47% |
| MRK | $79.44 | -1.67% | 199.5B | 12.24 | $6.49 | +3.97% |
| AMGN | $284.67 | -5.14% | 153.1B | 23.26 | $12.24 | +3.26% |
| GILD | $110.28 | -1.94% | 137.2B | 14.25 | $7.74 | +2.80% |
| PFE | $23.93 | -3.31% | 136.1B | 12.67 | $1.89 | +7.04% |
Stock Comparison
NVO vs LLY Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, LLY has a market cap of 707.6B. Regarding current trading prices, NVO is priced at $45.38, while LLY trades at $746.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas LLY's P/E ratio is 60.90. In terms of profitability, NVO's ROE is +0.81%, compared to LLY's ROE of +0.77%. Regarding short-term risk, NVO is more volatile compared to LLY. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check LLY's competition here
NVO vs JNJ Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, JNJ has a market cap of 410.7B. Regarding current trading prices, NVO is priced at $45.38, while JNJ trades at $170.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas JNJ's P/E ratio is 18.26. In terms of profitability, NVO's ROE is +0.81%, compared to JNJ's ROE of +0.30%. Regarding short-term risk, NVO is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check JNJ's competition here
NVO vs ABBV Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, ABBV has a market cap of 346.7B. Regarding current trading prices, NVO is priced at $45.38, while ABBV trades at $196.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas ABBV's P/E ratio is 93.47. In terms of profitability, NVO's ROE is +0.81%, compared to ABBV's ROE of +0.86%. Regarding short-term risk, NVO is more volatile compared to ABBV. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check ABBV's competition here
NVO vs AZN Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, AZN has a market cap of 228.2B. Regarding current trading prices, NVO is priced at $45.38, while AZN trades at $73.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas AZN's P/E ratio is 27.67. In terms of profitability, NVO's ROE is +0.81%, compared to AZN's ROE of +0.20%. Regarding short-term risk, NVO is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check AZN's competition here
NVO vs NVS Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, NVS has a market cap of 220.8B. Regarding current trading prices, NVO is priced at $45.38, while NVS trades at $113.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas NVS's P/E ratio is 16.55. In terms of profitability, NVO's ROE is +0.81%, compared to NVS's ROE of +0.23%. Regarding short-term risk, NVO is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check NVS's competition here
NVO vs MRK Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, MRK has a market cap of 199.5B. Regarding current trading prices, NVO is priced at $45.38, while MRK trades at $79.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas MRK's P/E ratio is 12.24. In terms of profitability, NVO's ROE is +0.81%, compared to MRK's ROE of +0.38%. Regarding short-term risk, NVO is more volatile compared to MRK. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check MRK's competition here
NVO vs AMGN Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, AMGN has a market cap of 153.1B. Regarding current trading prices, NVO is priced at $45.38, while AMGN trades at $284.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas AMGN's P/E ratio is 23.26. In terms of profitability, NVO's ROE is +0.81%, compared to AMGN's ROE of +0.93%. Regarding short-term risk, NVO is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check AMGN's competition here
NVO vs GILD Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, GILD has a market cap of 137.2B. Regarding current trading prices, NVO is priced at $45.38, while GILD trades at $110.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas GILD's P/E ratio is 14.25. In terms of profitability, NVO's ROE is +0.81%, compared to GILD's ROE of +0.32%. Regarding short-term risk, NVO is more volatile compared to GILD. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check GILD's competition here
NVO vs PFE Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, PFE has a market cap of 136.1B. Regarding current trading prices, NVO is priced at $45.38, while PFE trades at $23.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas PFE's P/E ratio is 12.67. In terms of profitability, NVO's ROE is +0.81%, compared to PFE's ROE of +0.12%. Regarding short-term risk, NVO is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check PFE's competition here
NVO vs SNY Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, SNY has a market cap of 112.6B. Regarding current trading prices, NVO is priced at $45.38, while SNY trades at $46.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas SNY's P/E ratio is 15.44. In terms of profitability, NVO's ROE is +0.81%, compared to SNY's ROE of +0.12%. Regarding short-term risk, NVO is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check SNY's competition here
NVO vs CELG-RI Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, CELG-RI has a market cap of 93.3B. Regarding current trading prices, NVO is priced at $45.38, while CELG-RI trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.81%, compared to CELG-RI's ROE of +0.30%. Regarding short-term risk, NVO is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check CELG-RI's competition here
NVO vs BMY Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, BMY has a market cap of 91.2B. Regarding current trading prices, NVO is priced at $45.38, while BMY trades at $44.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas BMY's P/E ratio is 18.00. In terms of profitability, NVO's ROE is +0.81%, compared to BMY's ROE of +0.30%. Regarding short-term risk, NVO is more volatile compared to BMY. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check BMY's competition here
NVO vs GSK Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, GSK has a market cap of 74.2B. Regarding current trading prices, NVO is priced at $45.38, while GSK trades at $36.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas GSK's P/E ratio is 16.72. In terms of profitability, NVO's ROE is +0.81%, compared to GSK's ROE of +0.24%. Regarding short-term risk, NVO is more volatile compared to GSK. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check GSK's competition here
NVO vs HZNP Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, NVO is priced at $45.38, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas HZNP's P/E ratio is 61.86. In terms of profitability, NVO's ROE is +0.81%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, NVO is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check HZNP's competition here
NVO vs BIIB Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, BIIB has a market cap of 19B. Regarding current trading prices, NVO is priced at $45.38, while BIIB trades at $129.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas BIIB's P/E ratio is 12.38. In terms of profitability, NVO's ROE is +0.81%, compared to BIIB's ROE of +0.09%. Regarding short-term risk, NVO is more volatile compared to BIIB. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check BIIB's competition here
NVO vs GRFS Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, GRFS has a market cap of 9B. Regarding current trading prices, NVO is priced at $45.38, while GRFS trades at $10.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas GRFS's P/E ratio is 20.56. In terms of profitability, NVO's ROE is +0.81%, compared to GRFS's ROE of +0.05%. Regarding short-term risk, NVO is more volatile compared to GRFS. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check GRFS's competition here
NVO vs OGN Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, OGN has a market cap of 2.3B. Regarding current trading prices, NVO is priced at $45.38, while OGN trades at $8.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas OGN's P/E ratio is 3.24. In terms of profitability, NVO's ROE is +0.81%, compared to OGN's ROE of +1.82%. Regarding short-term risk, NVO is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check OGN's competition here
NVO vs CTOR Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, CTOR has a market cap of 149.7M. Regarding current trading prices, NVO is priced at $45.38, while CTOR trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas CTOR's P/E ratio is -5.03. In terms of profitability, NVO's ROE is +0.81%, compared to CTOR's ROE of -0.34%. Regarding short-term risk, NVO is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check CTOR's competition here
NVO vs SCLXW Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, SCLXW has a market cap of 111M. Regarding current trading prices, NVO is priced at $45.38, while SCLXW trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas SCLXW's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.81%, compared to SCLXW's ROE of +0.36%. Regarding short-term risk, NVO is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check SCLXW's competition here
NVO vs SCLX Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, SCLX has a market cap of 103.7M. Regarding current trading prices, NVO is priced at $45.38, while SCLX trades at $14.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas SCLX's P/E ratio is -0.98. In terms of profitability, NVO's ROE is +0.81%, compared to SCLX's ROE of +0.36%. Regarding short-term risk, NVO is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check SCLX's competition here
NVO vs MIRA Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, MIRA has a market cap of 24.9M. Regarding current trading prices, NVO is priced at $45.38, while MIRA trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas MIRA's P/E ratio is -3.04. In terms of profitability, NVO's ROE is +0.81%, compared to MIRA's ROE of -3.41%. Regarding short-term risk, NVO is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check MIRA's competition here
NVO vs SRXH Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, SRXH has a market cap of 12.6M. Regarding current trading prices, NVO is priced at $45.38, while SRXH trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas SRXH's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.81%, compared to SRXH's ROE of -0.50%. Regarding short-term risk, NVO is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check SRXH's competition here
NVO vs CRXT Comparison August 2025
NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 207.5B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, NVO is priced at $45.38, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 12.43, whereas CRXT's P/E ratio is -0.02. In terms of profitability, NVO's ROE is +0.81%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, NVO is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check CRXT's competition here